The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 2×
“HER-2 Breasta Trastuzumab Combination Slamon et al. (2001)28,b, Piccart-Gebhart et al. (2005)29,b”
BackgroundLynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419 · cited 3×
“EGFR NSCLCa Gefitinib, erlotinib Monotherapy Shepherd et al. (2005)32,b, Taron et al. (2005)35, Lynch et al. (2004)36”
BackgroundInfluentialTrastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Tumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559
Cited by
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
Angiogenesis: an organizing principle for drug discovery?
Folkman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2115 · Cited by 2,246
Pui, C.-H., Robison, L. L., & Look, A. T. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60457-2 · Cited by 1,564
Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis
Ouyang, L., Shi, Z., Zhao, S., Wang, F. ‐., Zhou, T. ‐., Liu, B., & Bao, J. ‐. (2012) · Cell Proliferation · doi:10.1111/j.1365-2184.2012.00845.x · Cited by 1,452
Cyclin D as a therapeutic target in cancer
Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3090 · Cited by 1,370
Transcriptional Addiction in Cancer
Bradner, J. E., Hnisz, D., & Young, R. A. (2017) · Cell · doi:10.1016/j.cell.2016.12.013 · Cited by 1,194
Parallel progression of primary tumours and metastases
Klein, C. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2627 · Cited by 1,133
Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
Wagle, N., Emery, C., Berger, M. F., Davis, M. J., Sawyer, A., Pochanard, P., Kehoe, S. M., Johannessen, C. M., MacConaill, L. E., Hahn, W. C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.2312 · Cited by 1,005
High-throughput oncogene mutation profiling in human cancer
Thomas, R. K., Baker, A. C., DeBiasi, R. M., Winckler, W., LaFramboise, T., Lin, W. M., Wang, M., Feng, W., Zander, T., MacConaill, L. E., et al. (2007) · Nature Genetics · doi:10.1038/ng1975 · Cited by 988
OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma
Medina, P. P., Nolde, M., & Slack, F. J. (2010) · Nature · doi:10.1038/nature09284 · Cited by 1,073
Drugging the ‘undruggable’ cancer targets
Dang, C. V., Reddy, E. P., Shokat, K. M., & Soucek, L. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.36 · Cited by 927
Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia
Palomero, T., Sulis, M. L., Cortina, M., Real, P. J., Barnes, K., Ciofani, M., Caparros, E., Buteau, J., Brown, K., Perkins, S. L., et al. (2007) · Nature Medicine · doi:10.1038/nm1636 · Cited by 877
Weinstein, I. B., & Joe, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3293 · Cited by 805
Self-citationMaitra, A., & Hruban, R. H. (2008) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathmechdis.3.121806.154305 · Cited by 707
The PI3K/AKT/mTOR interactive pathway
Ersahin, T., Tuncbag, N., & Cetin-Atalay, R. (2015) · Molecular BioSystems · doi:10.1039/c5mb00101c · Cited by 683
Williams, G. H., & Stoeber, K. (2012) · The Journal of Pathology · doi:10.1002/path.3022 · Cited by 661
Mechanisms and insights into drug resistance in cancer
Zahreddine, H., & Borden, K. L. B. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00028 · Cited by 660
Integrative Genomic Approaches Identify IKBKE as a Breast Cancer Oncogene
Boehm, J. S., Zhao, J. J., Yao, J., Kim, S. Y., Firestein, R., Dunn, I. F., Sjostrom, S. K., Garraway, L. A., Weremowicz, S., Richardson, A. L., et al. (2007) · Cell · doi:10.1016/j.cell.2007.03.052 · Cited by 617
FGF Receptors: Cancer Biology and Therapeutics: CANCER BIOLOGY AND THERAPEUTICS ON FGF RECEPTORS
Katoh, M., & Nakagama, H. (2014) · Medicinal Research Reviews · doi:10.1002/med.21288 · Cited by 610
Regulation and function of miRNA-21 in health and disease
Kumarswamy, R., Volkmann, I., & Thum, T. (2011) · RNA Biology · doi:10.4161/rna.8.5.16154 · Cited by 607
Gainor, J. F., Varghese, A. M., Ou, S.-H. I., Kabraji, S., Awad, M. M., Katayama, R., Pawlak, A., Mino-Kenudson, M., Yeap, B. Y., Riely, G. J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0318 · Cited by 604
Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents
Sharma, S. V., Haber, D. A., & Settleman, J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2820 · Cited by 586
Chan, A., Delaloge, S., Holmes, F. A., Moy, B., Iwata, H., Harvey, V. J., Robert, N. J., Silovski, T., Gokmen, E., von Minckwitz, G., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00551-3 · Cited by 561
Huang, S., Ernberg, I., & Kauffman, S. (2009) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2009.07.003 · Cited by 556
Measurement of biomarker proteins for point-of-care early detection and monitoring of cancer
Rusling, J. F., Kumar, C. V., Gutkind, J. S., & Patel, V. (2010) · The Analyst · doi:10.1039/c0an00204f · Cited by 552
Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises
Yap, T. A., Garrett, M. D., Walton, M. I., Raynaud, F., de Bono, J. S., & Workman, P. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.08.004 · Cited by 543
Choosing between glycolysis and oxidative phosphorylation: a tumor’s dilemma?
Jose, C., Bellance, N., & Rossignol, R. (2011) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2010.10.012 · Cited by 518
Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells
Shattuck, D. L., Miller, J. K., Carraway, K. L., & Sweeney, C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5962 · Cited by 473
The Hsp90 molecular chaperone: an open and shut case for treatment
Pearl, L. H., Prodromou, C., & Workman, P. (2008) · Biochemical Journal · doi:10.1042/bj20071640 · Cited by 447
Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in Cancer
Brooks, A. N., Kilgour, E., & Smith, P. D. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0699 · Cited by 446
Oncogene addiction: setting the stage for molecularly targeted cancer therapy
Sharma, S. V., & Settleman, J. (2007) · Genes & Development · doi:10.1101/gad.1609907 · Cited by 441
Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer Therapeutics
Chen, M. H., Kerkelä, R., & Force, T. (2008) · Circulation · doi:10.1161/circulationaha.108.776831 · Cited by 379
Translational Control in Cancer Etiology
Ruggero, D. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012336 · Cited by 367
From genes to drugs: targeted strategies for melanoma
Flaherty, K. T., Hodi, F. S., & Fisher, D. E. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3218 · Cited by 354
Rakhra, K., Bachireddy, P., Zabuawala, T., Zeiser, R., Xu, L., Kopelman, A., Fan, A. C., Yang, Q., Braunstein, L., Crosby, E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.002 · Cited by 339
Visceral obesity, metabolic syndrome, insulin resistance and cancer
Doyle, S. L., Donohoe, C. L., Lysaght, J., & Reynolds, J. V. (2012) · Proceedings of the Nutrition Society · doi:10.1017/s002966511100320x · Cited by 309
Schade, A. E., Schieven, G. L., Townsend, R., Jankowska, A. M., Susulic, V., Zhang, R., Szpurka, H., & Maciejewski, J. P. (2008) · Blood · doi:10.1182/blood-2007-04-084814 · Cited by 296
Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors
Vasan, N., Razavi, P., Johnson, J. L., Shao, H., Shah, H., Antoine, A., Ladewig, E., Gorelick, A., Lin, T.-Y., Toska, E., et al. (2019) · Science · doi:10.1126/science.aaw9032 · Cited by 283
Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches
Dietlein, F., Thelen, L., & Reinhardt, H. C. (2014) · Trends in Genetics · doi:10.1016/j.tig.2014.06.003 · Cited by 280
Zuber, J., Rappaport, A. R., Luo, W., Wang, E., Chen, C., Vaseva, A. V., Shi, J., Weissmueller, S., Fellman, C., Taylor, M. J., et al. (2011) · Genes & Development · doi:10.1101/gad.17269211 · Cited by 279
Kakadia, S., Yarlagadda, N., Awad, R., Kundranda, M., Niu, J., Naraev, B., Mina, L., Dragovich, T., Gimbel, M., & Mahmoud, F. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s182721 · Cited by 277
Mad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawal
Sotillo, R., Schvartzman, J.-M., Socci, N. D., & Benezra, R. (2010) · Nature · doi:10.1038/nature08803 · Cited by 273
Volinia, S., & Croce, C. M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304977110 · Cited by 149
UV-Induced Molecular Signaling Differences in Melanoma and Non-melanoma Skin Cancer
Liu-Smith, F., Jia, J., & Zheng, Y. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-56017-5_3 · Cited by 147
Fröhlich, F., Kessler, T., Weindl, D., Shadrin, A., Schmiester, L., Hache, H., Muradyan, A., Schütte, M., Lim, J.-H., Heinig, M., et al. (2018) · Cell Systems · doi:10.1016/j.cels.2018.10.013 · Cited by 143
“In the field of cancer research, mechanistic modeling has facilitated the study of oncogene addiction (Weinstein and Joe, 2006), synthetic-lethal phenotypes (Kaelin, 2005), and many other relevant phenomena (Zhang et al.”
BackgroundPunchihewa, C., Inoue, A., Hishiki, A., Fujikawa, Y., Connelly, M., Evison, B., Shao, Y., Heath, R., Kuraoka, I., Rodrigues, P., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.353201 · Cited by 135
De Smaele, E., Di Marcotullio, L., Moretti, M., Pelloni, M., Occhione, M. A., Infante, P., Cucchi, D., Greco, A., Pietrosanti, L., Todorovic, J., et al. (2011) · Neoplasia · doi:10.1593/neo.101630 · Cited by 92
Akgül, S., Patch, A.-M., D’Souza, R. C. J., Mukhopadhyay, P., Nones, K., Kempe, S., Kazakoff, S. H., Jeffree, R. L., Stringer, B. W., Pearson, J. V., et al. (2019) · Cancers · doi:10.3390/cancers11020190 · Cited by 57
Inflammation and survival pathways: Chronic lymphocytic leukemia as a model system
Chen, L. S., Balakrishnan, K., & Gandhi, V. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.07.039 · Cited by 55
An update on the implications of cyclin D1 in melanomas
González‐Ruiz, L., González‐Moles, M. Á., González‐Ruiz, I., Ruiz‐Ávila, I., Ayén, Á., & Ramos‐García, P. (2020) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12874 · Cited by 49
Novel Hsp90 partners discovered using complementary proteomic approaches
Tsaytler, P. A., Krijgsveld, J., Goerdayal, S. S., Rüdiger, S., & Egmond, M. R. (2009) · Cell Stress and Chaperones · doi:10.1007/s12192-009-0115-z · Cited by 46
Soto, D. R., Barton, C., Munger, K., & McLaughlin-Drubin, M. E. (2017) · PLOS Pathogens · doi:10.1371/journal.ppat.1006661 · Cited by 39
LKB1 drives stasis and C/EBP-mediated reprogramming to an alveolar type II fate in lung cancer
Murray, C. W., Brady, J. J., Han, M., Cai, H., Tsai, M. K., Pierce, S. E., Cheng, R., Demeter, J., Feldser, D. M., Jackson, P. K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28619-8 · Cited by 22
Weinstein, B. (2008) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-69080-3_1 · Cited by 17
Metadata
- Authors
- Weinstein, I. B., & Joe, A. K.
- Venue
- Nature Clinical Practice Oncology
- Published
- 2006-08
- Volume
- 3
- Issue
- 8
- Pages
- 448-457
- ISSN
- 1743-4254 (ISSN-L)
- 1743-4262
- OpenAlex
- W2147960762
- Cited by
- 705
- References
- 74
- FWCI
- 29.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.